U S Physical Therapy Inc (USPH) stock analysis
Close on Nov 11, 2026Market cap $1.49BP/E –Yield 1.80%
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed9 of 30 checks passed
U S Physical Therapy passes 9 of the 30 checks behind our score; 6 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 2/6
- Past performance
- 3/6
- Financial health
- 2/6
- Dividend
- 1/6
What stands out
Earnings grew over 5 years
Net income grew 2.4% a year on average over the last five fiscal years.
Revenue growing 10%+ a year
Revenue grew 12.2% a year over the last three fiscal years.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 36.1% of total debt.
P/B below the industry
U S Physical Therapy's price-to-book of 3.48 is below the Health Services median of 3.52.
What to watch
Margin of safety under 20%
The price is 22.0% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $100.10 is above our fair value estimate of $82.03.
Return on equity under 15%
Return on equity was 6.5% over the last twelve months and averaged 9.3% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 9.1%, below the 10% that usually covers the cost of capital.
Valuation1/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA above its 5-year median
U S Physical Therapy's EV/EBITDA of 17.3 is above its 5-year median of 16.0.
P/B below the industry
U S Physical Therapy's price-to-book of 3.48 is below the Health Services median of 3.52.
Trading above fair value
The share price of $100.10 is above our fair value estimate of $82.03.
Margin of safety under 20%
The price is 22.0% above fair value, so there is no margin of safety.
Growth2/6
Revenue growing 10%+ a year
Revenue grew 12.2% a year over the last three fiscal years.
EPS growing under 10% a year
Diluted EPS grew -14.2% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew -32.5% over the last twelve months, against a 5-year average of 2.4% a year.
Growing slower than the industry
Revenue grew 10.4% over the last twelve months; the Health Services median is 17.6%.
Guidance unchanged
The latest outlook (full year 2026 adjusted EBITDA, Aug 6, 2026) was maintained, so it neither adds nor takes away points.
Gross margin improving
Gross margin was 18.8% over the last twelve months, against 18.7% a year earlier.
Past performance3/6
Return on equity under 15%
Return on equity was 6.5% over the last twelve months and averaged 9.3% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 9.1%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
U S Physical Therapy's return on equity of 6.5% is above the Health Services median of -1.1%.
Earnings grew over 5 years
Net income grew 2.4% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 3.6% over the last twelve months, against a 5-year average of 5.7%.
Net margin above the industry
U S Physical Therapy's net margin of 3.6% is above the Health Services median of -13.7%.
Financial health2/6
High debt
Debt is 57.3% of shareholders' equity, above the 40% we consider low.
Debt rising against equity
Debt to equity rose from 7.8% five years ago to 57.3%.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 36.1% of total debt.
Interest coverage
Interest expense is not reported separately.
Short-term assets cover short-term debts
Current assets are 1.42 times current liabilities.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.85; above 3 is the safe zone and below 1.8 the distress zone.
Dividend1/6
Pays a dividend
U S Physical Therapy paid dividends worth 1.8% of the share price over the last twelve months.
Yield below Treasuries
The 1.8% yield is below the 4.4% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 3.8% or more; U S Physical Therapy yields 1.8%.
Dividend was cut
The dividend per share fell by more than 10% at least once in the last 10 fiscal years.
Earnings cover
Needs dividends paid and net income.
Cash-flow cover
Needs dividends paid and free cash flow.
Fair value
How we estimate itOur estimate per share
$82.03
The share price is 22% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| EV/EBITDA | 16.1× | 16.0× | 16.2× | $92.06 | 58% |
| P/B | 3.2× | 2.8× | 3.5× | $91.12 | 17% |
| Earnings power | 8.5% cost of equity | – | – | $52.58 | 25% |
| Fair value | $82.03 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 37.8
- Health Services median 23.9
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $16.79M
- Value traded per 1% price move
- $11.94M
Downside
Medium risk
- Typical loss in a bad month
- 19.6%
- Volatility (annualized)
- 38%
- Sharpe ratio, 1 year
- 0.85
- Beta to the S&P 500 (5Y)
- 0.72
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.3% | +12.2% | +13.0% | +9.0% | |
| Gross profit | +20.8% | +10.1% | +9.6% | +6.7% | |
| Operating income | +37.6% | +15.1% | +10.6% | +6.2% | |
| Net income | +26.0% | +7.2% | +2.4% | +6.7% | |
| EPS, diluted | -22.8% | -14.2% | -10.6% | -1.5% | |
| Free cash flow | -7.2% | +6.6% | -8.0% | +6.9% | |
| Dividend per share | +2.3% | +3.2% | +41.3% | +11.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.5% | 13.6% | 8.2% | |
| Return on assets | 6.3% | 5.7% | 3.3% | |
| Current ratio | 2.68 | 0.94 | 1.01 | |
| Debt to equity | 0.28 | 0.08 | 0.34 | |
| Net debt to EBITDA | 0.54× | -0.18× | 1.16× | |
| Interest coverage | 4.3× | – | – | |
| Capex to revenue | 2.3% | 1.8% | 1.8% | |
| Diluted shares | 13M | 13M | 15M |
Where the cash went
Fiscal 2021 to 2025, five years combined
U S Physical Therapy generated $366.92M from operations and spent $172.68M on capital expenditure, dividends and share buybacks. 28% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 5.1% | 0.66× | 2.46× | 8.2% |
| FY2024 | 4.7% | 0.62× | 2.24× | 6.5% |
| FY2023 | 4.7% | 0.65× | 2.34× | 7.1% |
| FY2022 | 5.8% | 0.69× | 2.63× | 10.5% |
| FY2021 | 8.2% | 0.74× | 2.35× | 14.3% |
| FY2020 | 8.3% | 0.69× | 2.37× | 13.6% |
| FY2019 | 8.3% | 0.90× | 2.35× | 17.6% |
| FY2018 | 7.7% | 1.05× | 2.05× | 16.6% |
| FY2017 | 5.4% | 1.08× | 1.96× | 11.3% |
| FY2016 | 5.8% | 1.09× | 1.83× | 11.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$39.58M
- Cash generatingOperating cash flow above zero$75.06M
- Return on assets improvedROA up on the prior year3.2% → 3.4%
- Earnings backed by cashOperating cash flow above net income$75.06M vs $39.58M
- Less leverageLong-term debt to assets fell12.2% → 12.7%
- Better liquidityCurrent ratio rose1.18 → 1.01
- No dilutionShare count did not rise15M → 15M
- Gross margin improvedGross margin up on the prior year18.46% → 19.17%
- More efficientAsset turnover rose0.67 → 0.67
See a number that looks wrong?